Search Results for "quinidine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for quinidine. Results 1 to 7 of 7 total matches.
See also: Nuedexta

Dextromethorphan/Bupropion (Auvelity) for Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
suppressant; it is also FDA-approved in a fixed-dose combination with quinidine (Nuedexta) for treatment ...
The FDA has approved an extended-release fixed-dose combination of dextromethorphan and bupropion (Auvelity – Axsome) for treatment of major depressive disorder (MDD) in adults.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):201-3 |  Show IntroductionHide Introduction

Table: Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023  (Issue 1669)
Inhibitors Inducers 2D6 bupropion cinacalcet fluoxetine paroxetine quinidine quinine terbinafine ...
View the Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters tables
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e28-30   doi:10.58347/tml.2023.1669g |  Show IntroductionHide Introduction

Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
behavioral and psychological symptoms of dementia, including agitation.3 Dextromethorphan/quinidine ...
The FDA has approved the oral second-generation antipsychotic drug brexpiprazole (Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated with dementia due to Alzheimer's disease (AD). Brexpiprazole is the first drug to be approved in the US for this indication. It is also approved for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):99-101   doi:10.58347/tml.2023.1679b |  Show IntroductionHide Introduction

Drugs for Dementia

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026  (Issue 1751)
DEXTROMETHORPHAN/QUINIDINE — A fixed-dose combination of dextromethorphan, an uncompetitive NMDA receptor ...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2026 Mar 30;68(1751):49-56   doi:10.58347/tml.2026.1751a |  Show IntroductionHide Introduction

Gepotidacin (Blujepa) — A New Antibiotic for Uncomplicated UTI

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2026  (Issue 1745)
by CYP3A4; use with such drugs that have a narrow therapeutic index (e.g., quinidine, cyclosporine) should ...
The FDA has approved gepotidacin (Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients ≥12 years old who weigh ≥40 kg. Gepotidacin is the first triazaacenaphthylene antibiotic to be approved in the US.
Med Lett Drugs Ther. 2026 Jan 5;68(1745):1-3   doi:10.58347/tml.2026.1745a |  Show IntroductionHide Introduction

Two New Drugs for Gonorrhea

   
The Medical Letter on Drugs and Therapeutics • Mar 16, 2026  (Issue 1750)
with narrow therapeutic indices (e.g., quinidine, cyclosporine) should be avoided. It can also increase ...
The FDA has approved two antibiotics, gepotidacin (Blujepa — GSK) and zoliflodacin (Nuzolvence — Entasis), for oral treatment of uncomplicated urogenital gonorrhea in patients ≥12 years old. Gepotidacin is approved for use in persons weighing ≥45 kg who have limited or no alternative treatment options; it was approved in 2025 for treatment of uncomplicated urinary tract infection in females. Zoliflodacin is approved for use in persons weighing ≥35 kg. Neither drug is indicated for treatment of rectal or pharyngeal gonorrhea.
Med Lett Drugs Ther. 2026 Mar 16;68(1750):41-3   doi:10.58347/tml.2026.1750a |  Show IntroductionHide Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024  (Issue 1693)
is required with coadministration of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin ...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8   doi:10.58347/tml.2024.1693a |  Show IntroductionHide Introduction